Xcout Intel
Forty Seven competitors & alternatives
The 12 closest competitors and alternatives to Forty Seven among healthcare companies — ranked by similarity to what Forty Seven actually does, not by market-cap band.
Subscribe to see Forty Seven’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Forty Seven
Forty Seven, Inc. is a clinical-stage immuno-oncology company headquartered in Menlo Park, California, that develops therapies targeting cancer immune evasion pathways.
Forty Seven at a glance
Forty Seven is a healthcare company headquartered in United States. It has raised at least $184.1M across the 3 funding rounds on record. Its most recent funding round, Series B, raised $75M in October 2017. Xcout tracks 17 named people at Forty Seven, including Daniel O'Day (Chairman and Chief Executive Officer, Gilead Sciences).
Forty Seven leadership
- Daniel O'DayChairman and Chief Executive Officer, Gilead Sciences
- Andrew DickinsonChief Financial Officer
- Dietmar BergerChief Medical Officer
- Johanna MercierChief Commercial & Corporate Affairs Officer
- Cindy PerettieExecutive Vice President, Kite
- Flavius MartinExecutive Vice President, Research
11 more named people on record for Forty Seven, with roles, board committees and tenure — see the full roster →
Forty Seven funding rounds
At least $184.1M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $75M | 1 named | |
| Series B | $75M | 1 named | |
| SEC Form D filing | $34.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Forty Seven competitors
Ranked by semantic similarity — how close each company is to Forty Seven by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar healthcare company
Gritstone bio, Inc. is a clinical-stage biotechnology company headquartered in Emeryville, California. The firm engages in developing next-generation cancer immunotherapies and vaccines to fight various forms of cancer and infectious diseases.
Similar healthcare company
Eigen Therapeutics is a biotechnology company headquartered in Redwood City, California, focused on developing 'priming' therapies that make cancer easier to find and eliminate.
Similar healthcare company
Nuvig Therapeutics, Inc. is a company headquartered in Palo Alto, California, dedicated to developing novel immune and therapeutic treatments for chronic autoimmune diseases.
Similar healthcare company
GEn1E Lifesciences Inc. is a clinical-stage, Phase 2 biotechnology research company based in Palo Alto, California, focused on accelerating novel precision therapies.
Health Care
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company that develops novel immunotherapies and macrophage-targeting treatments for cancer patients. Its lead candidate, bexmarilimab, is an anti-Clever-1 antibody being evaluated in clinical trials for hematological cancers and solid tumors to improve the efficacy of standard cancer treatments.
Similar healthcare company
Harbour BioMed is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology.
Similar healthcare company
GENEOS Therapeutics, Inc. is a biotechnology company focused on developing exquisitely personalized, EPIC-based cancer immunotherapies. The company is headquartered in Philadelphia, Pennsylvania, United States.
Biotechnology
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
Biotechnology
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with an additional office in Belgium. The company focuses on discovering and developing novel immuno-oncology therapeutics for cancer treatment.
Biotechnology
Surface Oncology is a clinical-stage biotechnology company focused on developing immunotherapies that target the tumor microenvironment and enhance anti-tumor immune responses. Its programs are intended for cancer patients and are developed for use by oncology physicians and healthcare systems, with potential pharmaceutical partnerships.
Biotechnology
PeproMene Bio, Inc. is a clinical-stage biotechnology company located in Irvine, California, dedicated to developing novel therapies targeting BAFF-R to treat cancers and immune diseases.
Biotechnology
ImCheck Therapeutics designs and develops next-generation immunotherapeutic antibodies focused on modulating the immune system through the butyrophilin and butyrophilin-like superfamily of checkpoint molecules. The company's pipeline targets treatments for cancer, infectious disease, and autoimmune disease.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Forty Seven and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Forty Sevenand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →